Independent peptide education · Evidence annotated · Research use information
Peptide Library / TB-500

TB-500 Research Guide

Synthetic peptide related to thymosin beta-4

Preclinical
ClassificationSingle Peptide
Evidence tierPreclinical
Research statusEducational reference
01 · At a glance

Overview

TB-500 is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.

Dosing & reconstitution guide

TB-500 suggested dosing guide

A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.

Research protocol only
Suggested starting rangeNo approved human dose
Typical reference range2–5 mg commonly discussed
FrequencyTwice weekly loading protocols are commonly described
TimingSpace doses across the week
Typical durationOften described as 4–6 weeks before less frequent maintenance
RouteSubcutaneous injection

Titration and protocol notes

Commercial TB-500 protocols are not validated clinical regimens.

Annotated dosage protocol

Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.

PhaseDoseScheduleWhat this dosage means
Lower referenceNo approved human doseTwice weekly loading protocols are commonly describedThe lower end reported in research discussions; it is not a validated human starting prescription.
Commonly cited range2–5 mg commonly discussedSpace doses across the weekA range repeated in reference protocols. Repetition does not establish safety, efficacy, or an approved regimen.
Duration / reassessmentOften described as 4–6 weeks before less frequent maintenanceReassess before continuingCommercial TB-500 protocols are not validated clinical regimens. Dose changes should never be inferred from vial size or convenient syringe units.

TB-500 reconstitution example

This worked example uses a 10 mg vial, 2 mL of diluent, and a 2,500 mcg reference amount.

Vial strength10 mg
Diluent added2 mL
Concentration5 mg/mL
Example draw0.5 mL / 50 units
How this example is calculated: 10 mg ÷ 2 mL = 5 mg/mL. The 2,500 mcg reference amount equals 2.5 mg. That produces a 0.5 mL draw, or 50 units on a U-100 syringe.

Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.

Safety, handling, and storage
  • Suggested ranges are educational summaries, not individualized prescriptions.
  • FDA-labeled regimens apply only to the approved product, indication, and delivery system.
  • For experimental compounds, human safety, purity, and effective dosing may be unknown.
  • Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Live concentration math

TB-500 calculator

Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.

Runs in your browser
Concentration5 mg/mL
Draw volume0.5 mL
On the syringe50 units
Portions per vial4

Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.

02 · How it is studied

Mechanism and research rationale

Thymosin beta-4 biology involves actin binding, cell migration and repair signaling. Commercial TB-500 preparations are not equivalent to an approved medicine.

Cell migration

Tissue repair

Angiogenesis

03 · Interpretation

Key facts

  • Evidence tier: Preclinical.
  • Research status and regulatory status are not interchangeable.
  • This page is an educational reference and does not provide personal medical instructions.
04 · Editorial annotations

What to keep in mind

Editorial note: distinguish peer-reviewed findings from supplier or community claims.
Evidence note: study design, species, route and formulation can materially change interpretation.
05 · Sources

References and evidence indexes

  1. PubMed search: TB-500
  2. ClinicalTrials.gov search
Research product

Looking for TB-500?

View the corresponding TB-500 research product, specifications, and available documentation from Novatherix Laboratories.

View at Novatherix →

External catalog link. For qualified laboratory and research use only.

Research notice: This guide is educational and not medical advice. It does not diagnose, treat, prescribe, or recommend personal use.